TransMedics Group, Inc. (TMDX) Stock Analysis
A live, multi-source view of TransMedics Group, Inc. (TMDX): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Sector: Healthcare · Industry: Medical Devices · United States · 898 employees · transmedics.com
Key statistics · as of 2026-09-06
As of 2026-09-06, TransMedics Group, Inc. (TMDX) had a market capitalization of $3.12B, a trailing P/E of 23.3 (forward 39.0) and a beta of 1.88; the shares traded in a 52-week range of $60.10 – $156.00 (-14.8% over the year).
- Market cap
- $3.12B
- Enterprise value
- $3.52B
- Trailing P/E
- 23.3
- Forward P/E
- 39.0
- PEG ratio
- 0.70
- Price / book
- 6.01
- EPS (trailing)
- $3.86
- EPS (forward)
- $2.31
- Payout ratio
- 0.0%
- 52-week range
- $60.10 – $156.00
- 52-week change
- -14.8%
- Beta
- 1.88
- Average volume
- 936,284
- Shares outstanding
- 34.7M
- Short % of float
- 35.52%
- Profit margin
- 22.7%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, TransMedics Group, Inc. (TMDX) last closed at $85.04 (the last completed close before that scan).
Technicals at the scan: RSI 48 (neutral territory), price -4.7% versus its 20-day average, 20-day versus 50-day average spread +9.8%, MACD histogram -0.98.
Sentiment inputs: 100% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 71/100.
Next scheduled company event: in 48 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for TMDX in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
TMDX has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls TransMedics Group, Inc. (TMDX) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell TMDX.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.